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The importance of the immune system in conferring protection against pathogens like
viruses, bacteria, and parasitic worms is well established. In contrast, there is a long-lasting
debate on whether cancer prevention is a primary function of the immune system.The con-
cept of immunological surveillance of cancer was developed by Lewis Thomas and Frank
Macfarlane Burnet more than 50 years ago. We are still lacking convincing data illustrating
immunological eradication of precancerous lesions in vivo. Here, I present eight types of
evidence in support of the cancer immunosurveillance hypothesis. First, primary immun-
odeficiency in mice and humans is associated with increased cancer risk. Second, organ
transplant recipients, who are treated with immunosuppressive drugs, are more prone to
cancer development.Third, acquired immunodeficiency due to infection by human immun-
odeficiency virus (HIV-1) leads to elevated risk of cancer. Fourth, the quantity and quality of
the immune cell infiltrate found in human primary tumors represent an independent prog-
nostic factor for patient survival. Fifth, cancer cells harbor mutations in protein-coding genes
that are specifically recognized by the adaptive immune system. Sixth, cancer cells selec-
tively accumulate mutations to evade immune destruction (“immunoediting”). Seventh,
lymphocytes bearing the NKG2D receptor are able to recognize and eliminate stressed
premalignant cells. Eighth, a promising strategy to treat cancer consists in potentiating the
naturally occurring immune response of the patient, through blockade of the immune check-
point molecules CTLA-4, PD-1, or PD-L1.Thus, there are compelling pieces of evidence that
a primary function of the immune system is to confer protection against cancer.
Keywords: cancer immunosurveillance, primary immunodeficiency, cancer risk, organ transplantation, immuno-
suppressive drugs, HIV, NKG2D, checkpoint blockade
INTRODUCTION
Lewis Thomas and Frank Macfarlane Burnet proposed the concept
of immunological surveillance of cancer more than five decades
ago (1–4). It was defined by Burnet as follows: “In large long-lived
animals, like most of the warm-blooded vertebrates, inheritable
genetic changes must be common in somatic cells and a propor-
tion of these changes will represent a step toward malignancy. It
is an evolutionary necessity that there should be some mechanism
for eliminating or inactivating such potentially dangerous mutant
cells and it is postulated that this mechanism is of immunologi-
cal character” (1). More than 50 years after Burnet proposed his
theory, the immunological scientific community remains largely
divided with both proponents [e.g., Ref. (5, 6)] and opponents
[e.g., Ref. (7, 8)] of the cancer immunosurveillance hypothesis. In
fact, an opposite and very influential concept was proposed in 2001
by Frances Balkwill and Alberto Mantovani, who suggested that
inflammatory immune cells and cytokines found in tumors may
promote rather than suppress tumor growth (9, 10). Although, we
are currently lacking convincing data illustrating immunological
eradication of precancerous lesions in vivo, there are strong indi-
cations that a primary function of the immune system is indeed to
prevent cancer. Here, I present eight types of evidence in support
of the cancer immunosurveillance hypothesis.
PRIMARY IMMUNODEFICIENCY IN HUMANS AND MICE IS
ASSOCIATED WITH INCREASED CANCER RISK
As Burnet himself pointed out, an implication of the can-
cer immunosurveillance hypothesis is that immunodeficiency
should be associated with increased likelihood of neoplasia (1).
Immunodeficiencies can be divided in two main types: pri-
mary (inborn) immunodeficiencies, which are caused by genetic
defects and whose incidence is approximately 1:10,000 births; and
secondary immunodeficiencies, which are induced by immuno-
suppressive medication or viral infection and which are much
more common. In accordance with Burnet’s prediction, severe
primary immunodeficiencies have been reported to be associ-
ated with increased risk of malignancy (11–14). For instance,
patients with defective humoral immunity due to common vari-
able immunodeficiency (CVID) had increased incidence of lym-
phoma and epithelial tumors of the stomach, breast, bladder,
and cervix (12, 15). Selective immunoglobulin A (IgA) defi-
ciency was associated with a high incidence of gastric carcino-
mas (15). Moreover, patients with X-linked immunodeficiency
with hyper-IgM, caused by mutations in the CD40 ligand mol-
ecule, had a high incidence of tumors of the pancreas and
liver (16). However, it remains unclear to what extent pri-
mary immunodeficiency in humans leads to increased cancer
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development, due to the relatively low number of patients
investigated.
Gene-targeted mice, which selectively lack key components
of the immune system have been extensively used to experi-
mentally test the effect of well-defined primary immunodefi-
ciencies on cancer development [reviewed in Ref. (17)]. Mice
which lacked both T and B cells, due to a deficiency in the
recombination-activating gene 2 (RAG2), were more susceptible
to spontaneous and carcinogen-induced carcinomas (18). Mice
lacking γδ T cells were highly susceptible to multiple regimens
of cutaneous carcinogenesis (19). The cytokines interferon-α/β
(IFN-α/β) and IFN-γ were shown to protect mice against sponta-
neous and carcinogen-induced malignancy (18, 20–22). Moreover,
the molecule perforin, which is used by cytotoxic lymphocytes
to kill target cells, was reported to be important for surveil-
lance of spontaneous lymphoma (23). Collectively, the human
and mouse data reveal a consistent association between primary
immunodeficiency and increased incidence of various types of
cancer.
ORGAN TRANSPLANT RECIPIENTS ARE MORE PRONE TO
CANCER DEVELOPMENT
A breakthrough in organ transplantation was the discovery of
immunosuppressive drugs such as cyclosporine A, which prevent
organ rejection by the adaptive immune system (24). Immuno-
suppressive medication is now standard treatment after organ
transplantation. Life-long treatment of thousands of transplanted
patients with immunosuppressive drugs was defined by Thomas
as a “human experiment” to test the cancer immunosurveillance
hypothesis (4). Already in 1973, an international registry-based
study of renal-transplant recipients from 30 countries revealed that
transplantation was associated with increased risk of developing
cancer, in particular lymphoma (25). A large cohort investiga-
tion of cancer risk after organ transplantation was performed
in the Nordic countries, in homogeneous populations with well-
documented cancer incidence, on nearly 6000 kidney recipients
(26). A two to fivefold excess risk was reported for cancers of
the colon, larynx, lung, bladder, prostate, and testis. Strikingly
high risks, 10-fold to 30-fold above normally expected levels,
were observed for cancers of the lip, skin (non-melanoma), kid-
ney, endocrine glands, cervix, and for non-Hodgkin’s lymphoma
(26). Another large study of kidney transplantation in 200,000
patients from 42 countries reported that the risk of developing
lymphoma was 12-fold higher for transplant recipients than that in
a matched non-transplanted population (27). Notably, the major-
ity of posttransplant lymphomas were associated with infection
with Epstein–Barr virus (EBV), which primarily infects B cells
and is known to cause B cell transformation (28). Thus, most
lymphomas arising in transplant patients were likely to be a sec-
ondary event resulting from reduced antiviral immunity, rather
than a direct effect of reduced antitumor immunity. However,
lymphomas not associated with EBV infection have also been
reported after transplantation (29). An investigation of 175,000
solid organ transplants in the USA revealed that increased cancer
risk occurred not only after kidney transplantation but also after
liver, heart, and lung transplantation (30). Risk was increased for
32 different malignancies, some related to known infections (e.g.,
anal cancer and Kaposi sarcoma) and others unrelated to infections
(e.g., lung cancer and melanoma). The most common malignan-
cies with elevated risk were non-Hodgkin lymphoma and cancers
of the lungs (30).
Very high rates of non-melanoma skin cancers have been
reported for Swedish (20–40%) and Australian (70%) popula-
tions 20 years after transplantation (31–33). Cutaneous types of
human papillomaviruses have been suggested to be the cause of
non-melanoma skin cancers such as squamous cell carcinoma
in immunosuppressed patients, but the epidemiological pieces
of evidence remain inconsistent (34). Strikingly, non-melanoma
skin tumors in the renal-transplant population of Queensland,
Australia, were reported to arise predominantly on chronically
sun-exposed skin (head, neck, and distal limbs), strongly suggest-
ing a causative role of ultraviolet (UV) light rather than oncogenic
viruses (33). Thus, life-long treatment of organ transplant recip-
ients with immunosuppressive drugs leads to increased risk of
developing many different types of cancer, some related to known
infections and others unrelated.
IMMUNOSUPPRESSION INDUCED BY INFECTION BY
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 LEADS TO
ELEVATED RISK FOR CANCER
The HIV-1 virus causes acquired immunodeficiency by selectively
infecting and killing CD4+ T cells. Accordingly, HIV-infected
patients, receiving or not antiviral treatments, possess reduced
levels of CD4+ T cells compared to non-infected individuals.
HIV-infected individuals have elevated risk for cancer linked to
oncogenic viruses such as Kaposi sarcoma (caused by human her-
pes virus 8), Hodgkin’s and non-Hodgkin’s lymphoma (EBV), anal
and cervical cancer (human papilloma virus), and liver cancer
(hepatitis B and C viruses). Kaposi sarcoma, non-Hodgkin’s lym-
phoma and cervical cancer are particularly frequent and are con-
sidered as acquired immunodeficiency syndrome (AIDS)-defining
cancers (35). However, several cancers that are not linked to onco-
genic viruses, like lung cancer and multiple myeloma, are also
more frequent in patients with HIV (35, 36). Lung cancer is the
most common non-AIDS-defining cancer and a leading cause of
mortality among HIV-infected individuals (37). For the majority
of patients with lung cancer, malignant transformation is known
to be caused by carcinogens present in cigarette smoke. Higher
smoking rates have been reported for HIV-infected populations.
After controlling for potential confounders including smoking, a
large cohort study of veterans (with 37,000 HIV-infected patients
and 75,000 healthy controls) concluded that HIV was an inde-
pendent risk factor for incident lung cancer (37). Importantly,
cancer incidence in HIV-infected individuals was found to be
inversely related to CD4+ T cell counts in blood, which supports
the association between immunosuppression and increased can-
cer risk (38). For instance, the risk of lung cancer was doubled
by CD4+ T counts in the range of 350–499 cells per micro-
liter blood compared to normal counts ≥500, and continued
to increase as the CD4+ T cell count fell (38). Thus, acquired
immunodeficiency by HIV infection, which selectively depletes
CD4+ T cells, leads to increased risk of developing many differ-
ent types of cancer, some related to known infections, and others
unrelated.
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QUANTITY AND QUALITY OF THE IMMUNE CELL INFILTRATE
IN HUMAN PRIMARY TUMORS REPRESENT AN
INDEPENDENT PROGNOSTIC FACTOR FOR PATIENT
SURVIVAL
All solid tumors are infiltrated by a variety of immune cells. For
many types of human cancers, an association has been reported
between the type, density, and location of immune cells within the
primary tumor and the clinical outcome [reviewed in Ref. (39)].
The number of intratumoral CD3+ T cells was shown to positively
correlate with longer survival of patients with epithelial ovarian
and colorectal cancers (40, 41). A high number of stromal CD4+
T cells were found to represent an independent positive prognos-
tic factor in non-small cell lung cancer (42). Tumor-infiltrating
CD8+ cytotoxic T cells were shown to predict clinical outcome in
colon, lung, and breast cancers (42–45). Concurrent infiltration by
both CD4+ and CD8+ T cells was reported to represent a favor-
able prognostic factor in esophageal squamous cell carcinoma and
non-small cell lung cancer, suggesting that both cell types cooper-
ate to fight cancer (46, 47). Among all CD4+ T cell subsets, Th1
cells seem to be particularly advantageous, as reported for col-
orectal, liver, and breast cancers (39, 40, 48, 49). In patients with
gastrointestinal stromal tumors (GIST), the intratumoral density
of CD3+ T cells and NKp46+ natural killer (NK) cells were found
to represent two independent prognostic factors for progression-
free survival (50). Notably, NK and T cells were detected in distinct
areas of tumor sections, suggesting that both cell types contributed
independently to GIST immunosurveillance (50). Furthermore, a
high tumor infiltration by CD68+ macrophages was associated
with prolonged survival in prostate, lung, and colon cancers (43,
51–54). Thus, for various types of human cancers, the quantity
and the quality of the immune response within the primary tumor
appear to represent an independent predictor for patient survival.
This correlation between immunological data and clinical out-
come strongly suggests that the immune system of the patient
had naturally mounted an antitumor immune response before
any treatment had started. The efficiency of this response presum-
ably varies from patient to patient, thereby critically influencing
survival.
CANCER CELLS HARBOR MUTATIONS IN PROTEIN-CODING
GENES THAT ARE SPECIFICALLY RECOGNIZED BY THE
ADAPTIVE IMMUNE SYSTEM
Cancer cells originate from normal cells that have accumulated
“driver” mutations, which either activate oncogenes by dominant
gain of function or inactivate tumor suppressor genes by recessive
loss of function. A typical tumor contains two to eight of these
driver mutations (55). Cancer cells also accumulate “passenger”
mutations, which do not contribute to tumorigenesis. Genome-
wide sequencing studies have provided detailed information about
somatic mutations in various types of cancers. For common solid
tumors such as breast, colon, brain, and pancreas cancers, an
average of 30–60 non-synonymous mutations in protein-coding
genes was observed (56–59). Most of these mutations (95%) were
single-nucleotide substitutions, whereas the remainder was dele-
tions or insertions (55). Metastatic melanoma and non-small cell
lung carcinoma, which represent two types of cancers caused by
potent mutagens (UV light and cigarette smoke, respectively), had
a higher mutation rate with ~150 mutations per tumor (60, 61).
Pediatric tumors and leukemias had the fewest mutations with
~10 mutations per tumor on average (55). Thus, it is now estab-
lished that tumor cells in most cancer types harbor numerous
non-synonymous mutations in protein-coding genes.
Driver and passenger mutations, which alter the normal amino
acid sequence of proteins, may potentially be recognized by the
adaptive immune system. A number of studies have revealed that
tumor-specific antigens created by mutations can be recognized
either by the T cells or the B cells of the patient. For instance in
melanoma, CD4+ T cells were found that recognized a tumor-
specific antigen generated by a non-synonymous point mutation
in the gene coding for triosephosphate isomerase (62). Another
antigen recognized by CD4+ T cells in melanoma had been gener-
ated by a chromosomal rearrangement resulting in a fusion of a low
density lipid receptor gene with a fucosyltransferase gene (63). In
colorectal cancer with microsatellite instability phenotype, CD4+
T cells were identified that recognized a frameshift mutation in
the transforming growth factor β receptor II (TGFβRII) (64). In
a melanoma patient, the tumor suppressor p16INK4a with a point
mutation was specifically recognized by cytotoxic CD8+ T cells
(65). In non-small cell lung cancer, several CD8+ T cell epitopes
created by point mutations have been reported (66–68). Moreover,
in chronic myeloid leukemia, cytotoxic CD8+ T cells specific for
a BCR-ABL fusion protein (resulting from the fusion of BCR and
ABL genes) were found (69). Tumor-specific IgG antibodies are
common in the serum of cancer patients, as revealed by serolog-
ical identification of antigens by recombinant expression cloning
(SEREX) technology (70). This powerful method has allowed the
identification of over 2000 tumor antigens recognized by autol-
ogous IgG, including the p53 tumor suppressor modified by a
point mutation (71). Collectively, these studies demonstrate that
the adaptive immune system is able to detect cancer by specifically
recognizing the mutated proteins of the malignant cells.
CANCER CELLS SELECTIVELY ACCUMULATE MUTATIONS TO
EVADE IMMUNE DESTRUCTION
Recognition of cancer cells by tumor-specific CD8+ T cells is
achieved by the presentation of antigenic peptides from mutated
proteins on major histocompatibility complex (MHC) class I mol-
ecules on the surface of cancer cells. In order to avoid recognition
and the resulting elimination by CD8+ T cells, cancer cells often
mutate key genes of the MHC class I antigen presentation pathway.
Downregulation of surface MHC class I molecules is a common
feature of human cancer cells [reviewed in Ref. (72)]. Several
mechanisms have been reported, including mutations in the β2-
microglobulin gene, which is required for MHC class I molecule
expression on the cell surface (73, 74). MHC haplotype loss in
various human tumors was shown to be caused by complete or
partial loss of chromosome 6, which harbor all MHC class I and
class II genes (except for β2-microglobulin) (75). On the basis of
its mutation pattern in cancer cells,β2-microglobulin was recently
included in a list of 74 tumor suppressor genes (55). A recent study
analyzed somatic point mutations in exon sequences from 4742
human cancers across 21 cancer types (76). Based on mutation
frequency and pattern, 254 “cancer genes” were identified, includ-
ing four genes belonging to the MHC class I antigen presentation
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pathway (β2-microglobulin, HLA-A, HLA-B, and TAP1), as well
as the CD1D gene, which is involved in the presentation of lipid
antigens to NK T cells (76). Hence, several mutations frequently
observed in cancer cells are likely to result from selective pres-
sure to evade the immune attack, in particular by cytotoxic CD8+
T cells and NK T cells.
Another strategy used by cancer cells to avoid the immune
response consists of secreting immunosuppressive cytokines such
as transforming growth factor β (TGF-β) and interleukin 10
(IL-10). In contrast to normal cells, which produce very little,
malignant cells often secrete large amounts of TGF-β and IL-10
[reviewed in Ref. (77)]. Both cytokines have various effects on
non-transformed cells present in the tumor mass, most notably
the inhibition of immune cell functions. For several types of can-
cers, elevated serum levels of TGF-β or IL-10 have been reported
to be associated with worse prognosis [reviewed in Ref. (77)]. Sur-
prisingly, TGF-β can function both as a tumor suppressor and
a tumor promoter, this duality being known as the TGF-β para-
dox. In early stage tumors, TGF-β is a potent inducer of growth
arrest. In advanced stage malignant cells, TGF-β signaling path-
ways are severely dysregulated, and TGF-βpromotes tumor growth
[reviewed in Ref. (78)]. Thus, cancer cells often produce abnor-
mally high levels of immunosuppressive cytokines, which strongly
suggests that dampening immunity is a prerequisite for tumor
growth.
Experiments with immunodeficient mice have demonstrated
that the immune system may exert a strong selective pressure
on the cancer cells. By using the chemical carcinogen methyl-
cholanthrene, sarcomas were induced either in wild-type mice or
in RAG2-deficient mice, which lack both T and B cells (18). When
transplanted into RAG2-deficient mice, all sarcomas grew pro-
gressively with equivalent kinetics. In contrast, when the tumor
cells were injected into immunocompetent wild-type hosts, all
sarcomas from wild-type mice grew progressively, while 8 of 20
(40%) sarcomas from RAG2-deficient mice were rejected (18).
These data strongly suggest that in wild-type mice, there was
selection of tumor cells that were more capable of surviving in
an immunocompetent host. This provides an explanation for
the apparent paradox of tumor formation in immunologically
intact individuals. Based on these findings, Robert Schreiber and
coworkers introduced the term “cancer immunoediting,” which
was further developed into a general theory, to describe the sculpt-
ing actions of the immune response on developing tumors in
immunocompetent individuals (18, 79).
LYMPHOCYTES BEARING THE NKG2D RECEPTOR ARE ABLE
TO RECOGNIZE AND ELIMINATE STRESSED PREMALIGNANT
CELLS
NK cells are innate lymphocytes that can kill malignant or infected
cells. All NK cells and some T cells express the NKG2D molecule on
the cell surface. NKG2D is an activating receptor, which serves as a
major recognition receptor for detection and elimination of trans-
formed cells (80). The ligands for NKG2D are self proteins that are
poorly expressed by normal resting cells but upregulated on the
surface of stressed cells. NKG2D ligands in humans include MICA,
MICB, and six different ULBP proteins (81). In mice, NKG2D lig-
ands include MULT1, five isoforms of RAE-1, and three isoforms
of the H60 proteins (82). In humans, cells that express NKG2D
ligands may be recognized and killed by either NK cells or γδ T
cells in a process called lymphoid stress surveillance (83).
NKG2D ligands were shown to be upregulated in normal cells
after treatment with DNA-damaging agents like ionizing radia-
tions and UV light (84). It was concluded that the DNA damage
response, which was known to arrest the cell cycle and enhance
DNA repair, may also participate in alerting the immune system
to the presence of potentially dangerous cells (84). Several studies
suggested that expression of NKG2D ligands on transformed cells
may be directly induced by oncogenes. For example, the BCR-ABL
fusion oncogene was reported to control the expression of MICA
in chronic myelogenous leukemia cells at the posttranscriptional
level (85). Activation of the Ras oncogene was shown to upregu-
late the expression of RAE-1α/β in mouse cells, and ULBP1–3 and
MICA/B in human cells (86). In a recent study, surface upregula-
tion of NKG2D ligands by human epithelial cells in response to
UV irradiation, osmotic shock, or oxidative stress, was shown to
depend on the activation of the epidermal growth factor recep-
tor (EGFR) (87). The EGFR pathway is frequently dysregulated
in human cancer and it was proposed that activation of EGFR
may regulate the immunological visibility of stressed premalignant
cells (87). Surprisingly, several isoforms of RAE-1, like RAE-1ε,
were found to be expressed not only by cancer cells, but also by
some normal proliferating cells such as fibroblasts (88). The E2F
transcription factor, which controls cell cycle entry, was shown
to regulate RAE-1ε expression. These data suggest that NKG2D-
bearing lymphocytes may control the proliferation of both normal
and malignant cells (88).
MICA and MICB were found to be expressed by many, but
not all, freshly isolated carcinomas of the lung, breast, kidney,
ovary, prostate, colon, and liver (89, 90). Moreover, in vitro stud-
ies revealed that MICA and MICB contributed to the lysis of
hepatocellular carcinoma cells by NK cells (90). The importance
of NKG2D for cancer immunosurveillance in vivo gained sup-
port from experiments showing that cancer cells transfected with
NKG2D ligands and injected into mice were rapidly rejected by
NK cells and by CD8+ T cells (91, 92). Moreover, neutraliza-
tion of NKG2D with blocking monoclonal antibodies rendered
mice more susceptible to carcinogen-induced fibrocarcinoma
(93). Gene-targeted mice deficient for NKG2D were shown to be
more susceptible to the in situ development of prostate adeno-
carcinoma and B cell lymphoma (94). In humans, an association
has been reported between polymorphisms of the NKG2D gene
and susceptibility of developing liver and cervix cancers, support-
ing a protective role of NKG2D against these malignancies (95,
96). Thus, the expression of stress-induced endogenous molecules
associated with cell transformation is used by the immune system
to recognize and eliminate premalignant cells in mice and humans.
PROMISING NOVEL STRATEGY TO TREAT CANCER
CONSISTS IN POTENTIATING THE NATURALLY OCCURRING
IMMUNE RESPONSE OF THE PATIENT THROUGH BLOCKADE
OF IMMUNE CHECKPOINT MOLECULES
Activation of a naïve T cell requires at least two signals: T cell
receptor-mediated recognition of a cognate antigen (signal 1)
and engagement of the costimulatory receptor CD28 (signal 2).
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Once activated, T cells upregulate on the cell surface two co-
inhibitory molecules, cytotoxic T lymphocyte-associated antigen
4 (CTLA-4) and programed death 1 (PD-1). The function of these
co-inhibitory molecules is to tightly regulate the immune response
by containing excessive T cell activation. For the purpose of cancer
immunotherapy, monoclonal antibodies have been generated to
potentiate the ongoing antitumor immune response of the patient,
through “immune checkpoint blockade” of CTLA-4, PD-1, or PD-
1 ligand (PD-L1). The outcome of the initial clinical trials with
these new treatments is remarkable (97).
In a phase 3, randomized trial, the CTLA-4 blocking antibody
ipilimumab was shown to prolong survival of patients with previ-
ously treated metastatic melanoma by ~4 months (98). This was
a breakthrough in the treatment of metastatic melanoma because
no other therapy had previously been shown to prolong survival
in a phase 3 controlled trial. Another phase 3 trial with previ-
ously untreated metastatic melanoma patients showed that the
overall survival was significantly longer in the group receiving ipil-
imumab combined with the chemotherapy drug dacarbazine than
in the group receiving dacarbazine plus placebo (11 vs. 9 months)
(99). Moreover, higher survival rates after 3 years were observed in
the ipilimumab–dacarbazine group compared to controls (21 vs.
12%) (99).
Although no phase 3 trial has yet been published based on PD-
1 or PD-L1 blockade, phase 1 studies showed promising results.
PD-1 checkpoint blockade was tested in a phase 1 trial on patients
with several types of advanced cancer. Cumulative response rates
(complete or partial responses) were 18% among patients with
non-small cell lung cancer (14 of 76 patients), 28% among patients
with melanoma (26 of 94 patients), and 27% among patients with
renal-cell cancer (9 of 33 patients). Responses were durable, 20 of
31 responses lasting 1 year or more in patients with 1 year or more
of follow-up (100). In a phase 1 trial with anti-PD-L1 blocking
antibodies, an objective response (complete or partial response)
was observed in 9 of 52 patients with melanoma, 2 of 17 with
renal-cell cancer, and 5 of 49 with non-small cell lung cancer.
Responses lasted for 1 year or more in 8 of 16 patients with at least
1 year of follow-up (101). Finally, combined treatment of advanced
melanoma was performed with both anti-CTLA-4 and anti-PD-1
blocking antibodies in a phase 1 trial. The objective response rate
for all 53 treated patients in the concurrent-regimen group was as
high as 40% (102). Thus, immune checkpoint blockade represents
a promising new strategy to treat advanced cancer in humans.
The success of this approach, which is based on potentiating the
ongoing, naturally occurring antitumor immune response of the
patient, provides another piece of evidence that fighting cancer is
indeed a primary function of the immune system.
CONCLUDING REMARKS
As summarized in this review, the scientific literature over the past
50 years has provided strong support to the cancer immunosur-
veillance hypothesis. Thus, it appears that our immune system
does not only naturally protect us against infectious non-self
(pathogens) but also against malignant self (cancer). Many cell
types belonging to both the innate (NK cells and macrophages)
and the adaptive (T and B cells) immune systems seem to be
involved in cancer control. Our current understanding on how
the immune system fights cancer remains very fragmentary. There
are pieces of evidence for two main strategies used by the immune
system to distinguish cancer cells from normal cells. On one hand,
the adaptive immune system recognizes altered (mutated) self pro-
teins in malignant cells. On the other hand, NK cells and γδ T
cells recognize stress-induced self molecules (NKG2D ligands) on
transformed cells. Yet, cancer cells originate from normal cells and
a main challenge for successful antitumor immunity is to restrain
the destruction of normal cells (autoimmunity). In fact, a recent
study suggested that autoimmune disease may occur as a result of
an inaccurate antitumor immune response (103). Scleroderma is
an autoimmune connective tissue disease in which patients make
antibodies to a limited number of autoantigens, including the
RNA polymerase III subunit, encoded by the POLR3A gene. In
several patients who had both scleroderma and cancer, genetic
alterations of the POLR3A locus were found in the malignant cells,
suggesting that POLR3A mutations triggered an adaptive antitu-
mor immune response, which cross-reacted with normal tissue,
causing autoimmune disease (103).
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